Mars,
The manner in which the EBIT targets have been presented (i.e., wrt a FY15 base year) is highly unorthodox and the cynic in me tells me that it is designed that way to confound the less-diligent follower of the company.
Certainly, figures of "10% or 15% compared to base year" certainly come across a far more palatable at first glance than does "~5% pa".
PS. For context, I note that IFM has grown EBIT annual rates of by 8%, 29% and 13% pa over the past 3 financial years, so for the board to actively be designing a remuneration structure around a rate that is waaaaay below recent history begs a lot of questions.
At first pass, it smacks to me to being egregiously generous!
(And besides, a pure EBIT number - in isolation - is not a very useful determinant of shareholder wealth creation (management could simply acquire a whole swathe of EBIT at a silly multiple and they will get to where they want to be.)
I have some form in the past of operating in an activist capacity when the circumstances have warranted it.
To that end, I have built a financial model for IFM but I have not followed the executive travails of the business as well I sense you have.
When you have a moment, could you provide a thumbnail sketch of the sequence of events that led to the company coming to the position it currently finds itself, namely with the good guys seemingly sitting on the outside? I am assuming the founder stepped aside at some stage only to have the board morph into something he today finds incompatible with the interests of the company's shareholders.
- Forums
- ASX - By Stock
- IFM
- Richard Graham email regarding Performance Rights
IFM
infomedia ltd
Add to My Watchlist
4.51%
!
$1.28

Richard Graham email regarding Performance Rights, page-2
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.28 |
Change
0.055(4.51%) |
Mkt cap ! $482.4M |
Open | High | Low | Value | Volume |
$1.25 | $1.30 | $1.24 | $785.9K | 618.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 25000 | $1.26 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.30 | 44184 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 25000 | 1.260 |
1 | 4000 | 1.235 |
1 | 371 | 1.220 |
2 | 4958 | 1.200 |
1 | 20920 | 1.195 |
Price($) | Vol. | No. |
---|---|---|
1.300 | 24185 | 2 |
1.340 | 2250 | 1 |
1.350 | 162242 | 4 |
1.360 | 1862 | 1 |
1.370 | 16970 | 3 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
IFM (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online